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factors, SUA levels are associated with carotid IMT even in
subjects without the metabolic syndrome. This confirms
and expands the role of uric acid in the determinism of
CVD. Prospective trials would be useful to evaluate inter-
ventions aimed at lowering the uric acid level.
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Introduction
The positive association between serum uric acid (SUA)
and cardiovascular diseases (CVD) has been recognised by
several epidemiological studies [1–3]. However, whether
uric acid is an independent risk factor for cardiovascular
(CV) mortality is still disputed, as many studies suggest
that hyperuricaemia is associated with CVD because of
confounding factors such as obesity, dyslipidaemia, hyper-
tension, use of diuretics and insulin resistance [4, 5].
Elevated SUA levels are commonly seen in association
with glucose intolerance, hypertension and dyslipidaemia,
a cluster of disorders that characterise the metabolic syn-
drome [6–8]. Studies performed in healthy volunteers sug-
gest that the link between the metabolic syndrome and a
high SUA is related to insulin action in stimulating urate
reabsorption in the renal proximal tubule [9]. High-resolu-
tion ultrasound is a reliable, non-invasive method to detect
early structural and functional atherosclerotic changes in
the arterial wall. Increased carotid intima-media thickness
(IMT) is a structural marker of early atherosclerosis relat-
ed to vascular risk factors, and predicting CV events in dif-
ferent population groups [10, 11]. Finally, the relation
between SUA level and CVD has been investigated main-
ly in men. Therefore we evaluated the relationship of IMT
and SUA in postmenopausal women.
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Abstract Objective: Serum uric acid (SUA) is associated
with cardiovascular disease (CVD). However it is still dis-
puted whether the relationship is mediated by other risk
factors such as obesity, dyslipidaemia, hypertension and
insulin resistance. We explored the association of the uric
acid level with carotid intima-media thickness (IMT), a
well known marker of CVD, in postmenopausal healthy
women.  Methods: We consecutively enrolled post-
menopausal women undergoing a screening for health
evaluation. After an accurate clinical examination, and a
biochemical evaluation, the enrolled subjects underwent B
mode ultrasonography to assess common carotid intima
media thickness. Results: Among 234 women aged 45–70
years, the uric acid level is associated with carotid IMT
independently of other prognostic factors (p=0.03). In par-
ticular, women in the highest tertiles of uric acid level have
a greater IMT than women in the lowest tertile (p=0.007).
Conclusions: Independently of other cardiovascular risk
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Methods
We consecutively enrolled postmenopausal women undergoing
menopause health-screening tests in our University hospital. They
were all Caucasian, aged 45–75 years, in postmenopausal status,
defined as no natural menses for at least one year, and with a
serum FSH level more than 40 IU/l. Women with a history of
CVD were excluded from the study. The study was approved by
the local ethics committee, and all subjects provided informed
consent. An evaluation including collection of demographic infor-
mation, risk factors for CVD, medical history, medication use,
alcohol use, tobacco use and a physical examination to assess
blood pressure and anthropometric measurements were per-
formed. Venous blood was collected after overnight fasting, into
vacutainer tubes (Becton & Dickinson), and centrifuged within 4
h. Serum glucose, uric acid, creatinine, total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C) and triglycerides
were measured by standard laboratory techniques. Quality con-
trols were assessed daily for all determinations. Low-density
lipoprotein cholesterol (LDL-C) was calculated by the Friedewald
formula.
The ATP III criteria [12] were used to classify study partici-
pants as affected or not affected by the metabolic syndrome. In
brief, we based metabolic syndrome diagnosis on thepresence of
≥3 of the following factors: (1) waist circumference >88 cm, (2)
fasting triglycerides >150 mg/dl, (3) HDL-C <50 mg/dl, (4)
hypertension (systolic blood pressure ≥130 mmHg, diastolic
blood pressure ≥85 mmHg), and (5) fasting glucose ≥110 mg/dl.
The following criteria were used to define the CV risk factors:
diabetes: fasting blood glucose ≥126 mg/dl or antidiabetic treat-
ment; hyperlipidaemia: TC >200 mg/dl or triglycerides >200
mg/dl or lipid-lowering drugs use; hypertension: systolic blood
pressure >140 mmHg or diastolic blood pressure >90 mmHg or
antihypertensive treatment; tobacco use: present smokers.
Vascular ultrasound
The subjects underwent B-mode ultrasonography of the extracra-
nial carotid arteries by use of a duplex system (a high-resolution
ultrasound instrument ATL, HDI 5000 with a 5–12-MHz linear
array multifrequency transducer). All the examinations were per-
formed by the same ultrasonographer blinded to clinical infor-
mation. The right and left common carotid arteries (CCA) were
evaluated with the subjects in supine position, with the head
turned away from the sonographer, and the neck extended with
mild rotation. The IMT, defined as the distance between the inti-
ma-luminal interface and the media-adventitial interface, was
measured as previously described [13]. Briefly, in the posterior
approach and with the sound beam set perpendicular to the arte-
rial surface, 1 cm from the bifurcation, three longitudinal mea-
surements of IMT were completed on the right and left CCAs’far
wall, at sites free of any discrete plaques. The mean of the 3 right
and left longitudinal CCA-IMT measurements was then calculat-
ed. The coefficient variation of the methods was 3.3%. We eval-
uated only CCA because it is easier to image, with no missing
images; moreover the examination reproducibility is the best
among the different segments [14].
Statistical analysis
Differences in baseline demographic and clinical characteristics
among the groups were assessed by χ2-tests for categorical vari-
ables and unpaired Student’s t-test or ANOVA for continuous
variables. Pearson correlation coefficient was used to evaluate
variables associated to IMT. Multiple regression analysis was
used to obtain the relationship between IMT and SUA.
Covariates in adjusted models include age, and those significant-
ly correlated to carotid IMT. All reported p values are two-sided.
Significant differences were assumed to be present at p<0.05. All
comparisons were performed using the statistical package SPSS
11.0 for Windows.
Results
We enrolled 234 postmenopausal women; the mean age
was 56.4 years. All subjects completed the protocol study.
Demographic, clinical and biochemical characteristics and
prevalence of evaluated risk factors of the study population
are shown in Table 1. Only 3% of our population had
carotid IMT greater than 1 mm, a value known to predict
high CV risk in the elderly. No subjects had a history of
gout or a creatinine level >1.2 mg/dl. On the univariate
analysis age, TC, glucose, systolic blood pressure, smoking
and uric acid were positively correlated to IMT (Table 2),
therefore we performed a stepwise multiple regression
analysis. After this analysis the variables significantly cor-
related to carotid IMT were age (beta=0.330, p<0.001),
systolic blood pressure (beta=0.143, p=0.025) and SUA
(beta=0.133, p=0.030).
Table 1 Clinical and biochemical characteristics
Mean±SD
Age (years) 56.41±7.08
Body mass index (kg/m2) 28.45±5.27
Waist circumference (cm) 90.3±12.2
Systolic blood pressure (mmHg) 127.9±16.5
Diastolic blood pressure (mmHg) 77.9±8.7
Glucose (mg/dl) 98.5±21.8
Creatinine (mg/dl) 0.78±0.1
TC (mg/dl) 231.8±42.1
LDL-C (mg/dl) 145.96±35.8
HDL-C (mg/dl) 60.7±14.8
Triglycerides (mg/dl) 138.7±126.8
SUA (mg/dl) 4.2±1.1
IMT (mm) 0.69±0.15
Smokers (%) 20
Hypertension (%) 35
Hyperlipidaemia (%) 48
Diabetes (%) 5
Metabolic syndrome (%) 20After the population was divided into tertiles according
to SUA level, the IMT mean not adjusted for age (p=0.000)
and age adjusted (p=0.007) was significantly greater in the
second and third (highest) tertiles vs. the first (lowest) ter-
tile (Fig. 1).
We performed a multiple stepwise regression analysis
excluding subjects affected by metabolic syndrome (n=47,
20%), a syndrome linked to insulin resistance, as it was
suggested that the association between uric acid and CVD
is mediated by insulin resistance [15], and we found that
only age (beta=0.390, p<0.001) and SUA (beta=0.182,
p=0.006) are correlated to IMT. We also performed this
analysis in non-drinking women (n=124), as there is a
known relationship with alcohol intake [16], and the
Table 2 Pearson correlation coefficient and probability levels (p)
between risk factors or HRT and diuretic use and carotid IMT
Correlation coefficient p
Age 0.411 0.000
Body mass index 0.107 0.102
SBP 0.288 0.000
DBP 0.098 0.137
Glucose 0.131 0.045
Total cholesterol 0.156 0.017
LDL cholesterol 0.114 0.101
HDL cholesterol –0.097 0.155
Triglycerides 0.049 0.464
Serum uric acid 0.242 0.000
Creatinine 0.060 0.321
Smoking 0.168 0.01
HRT use 0.070 0.222
Diuretic use 0.069 0.296
Fig. 1 Not adjusted and age-adjusted
carotid intima-media thickness mean
according to serum uric acid tertiles (I,
lowest tertile; III, highest tertile)
results remain unchanged (data not shown). Finally we
performed a stepwise regression analysis excluding diuret-
ics users (n=26, 11%), as diuretics increase uric acid con-
centrations, and the correlations do not change.
Discussion
The main result of our study was to establish an associa-
tion between subclinical carotid atherosclerosis and uric
acid in postmenopausal women. Increased uric acid could
play a causative role in carotid and coronary atherosclero-
sis. It is well recognised that because of the loss of protec-
tive effect of oestrogens, postmenopausal women have an
increased prevalence of CVD. Wingrove et al. [17] demon-
strated that the uric acid concentration is significantly
higher in postmenopausal vs. premenopausal women,
moreover Nicholls et al. [18] found that oestrogen therapy
is able to reduce SUA levels. Therefore the increase of uric
acid as a consequence of oestrogen falls in menopause
could be one of the possible explanations of an increased
incidence of CVD in these women. In fact much, but not
all, epidemiological research identifies hyperuricaemia as
an independent risk factor for the development of CV and
renal disease, particularly in patients with hypertension or
congestive heart failure, and in women [1–5, 19].
Specifically in postmenopausal women it is found that the
mean value of uric acid increases linearly with the numer-
ical increase in coronary arteries with stenosis [20].
Recent findings from the LIFE study are consistent
with a role of uric acid in the development of CV disease.
In the cited study, up to one third of the CV benefit of
losartan vs. atenolol could be ascribed to the differences in
effect of these agents on SUA levels [21].
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IMOur results confirm that the relationship between uric
acid and carotid atherosclerosis should be considered as
independent as the exclusion of subjects affected by the
metabolic syndrome should be able to avoid interference
with the known confounding variables (obesity, dyslipi-
daemia, hypertension, insulin resistance).
Several possible pathologic mechanisms linking SUA to
CV disease have been proposed, including deleterious
effects on endothelial function, oxidative metabolism,
platelet adhesiveness, haemorheology and aggregation [22].
Moreover it is suggested that generation of uric acid
during ischaemia reperfusion contributes to atherogenesis
and intima proliferation following arterial injury [23].
Finally, increased amounts of uric acid are found in
carotid plaques, especially in those obtained from women
[24]. This result supports a role in the development of
cerebral atherosclerosis, also confirmed by the findings
that, not only in diabetic patients, but also in the general
population [25], uric acid is an independent predictor of
stroke. Our results seem to confirm this latter hypothesis,
with uric acid directly promoting atherosclerosis by wall
injury and consequent wall thickening. However, because
these explanations are beyond the aim of the present clini-
cal study, more elaborate studies are required to assess the
potential negative role of uric acid on atherosclerosis.
Study limitations
There are some study limitations. Firstly, the data analysis
was restricted to an observational study. Only a prospec-
tive study can confirm the interdependencies of changes in
SUA levels and CVD incidence. Secondly, no serum
insulin levels were measured to obtain an index of insulin
resistance. As insulin resistance is believed to play a major
role in the metabolic syndrome, the inclusion of this vari-
able in our statistical analysis would have been useful. On
the other hand, the analysis performed after exclusion of
subjects with the metabolic syndrome should ensure that
the association is present even in subjects without insulin
resistance.
Conclusions
Our study, together with others’studies, suggests that SUA
may be a tool to help to identify patients at high risk of
CVD, especially in postmenopausal women in apparent
good health, and in the absence of the metabolic syn-
drome. SUA should therefore be considered, along with
other risk factors, such as obesity, hyperlipidaemia, hyper-
glycaemia, hypertension and smoking in the assessment of
overall CV risk. The remaining key questions are whether
22
uric acid has a causal relation to CV disease, whether a
reduction can prevent carotid artery disease, and whether
uric acid can be reduced to an optimal level whereby it no
longer imposes an increased risk for CVD. These ques-
tions would be best approached through randomised clini-
cal trials.
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